Biomarin Pharmaceutical (BMRN) Cash from Operations (2009 - 2026)

Biomarin Pharmaceutical has disclosed Cash from Operations across 18 years of filings, most recently posting 220651000.0 for Q1 2026.

• Quarterly Cash from Operations rose 26.52% year-over-year to 220651000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 874251000.0 (up 24.85% YoY) and the FY2025 annual result came in at 827994000.0, up 44.54% from the prior year.
• Cash from Operations advanced to 220651000.0 in Q1 2026, from 99644000.0 in the prior quarter.
• Over five years, Cash from Operations peaked at 368685000.0 in Q3 2025 and troughed at 73932000.0 in Q1 2023.
• A 5-year average of 115096882.35 and a median of 118762000.0 in 2024 frame the typical range for Cash from Operations.
• Annual changes were most pronounced in 2022 — Cash from Operations plunged 140.02% — and 2024, when it surged 575.42%.
• Tracing BMRN's Cash from Operations over 5 years: stood at 6786000.0 in 2022, then surged by 305.0% to 27483000.0 in 2023, then jumped by 575.42% to 185627000.0 in 2024, then sank by 46.32% to 99644000.0 in 2025, then jumped by 121.44% to 220651000.0 in 2026.
• Business Quant data shows BMRN's Cash from Operations at 220651000.0 in Q1 2026, 99644000.0 in Q4 2025, and 368685000.0 in Q3 2025.